GLP-1
Semaglutide reduced body weight by nearly 15% in clinical trials and cut cardiovascular events by 20% in people with obesity and no diabetes. Here is the complete science-backed guide to Ozempic, Wegovy, and Rybelsus in 2026.
GLP-1
Semaglutide has become one of the most talked-about medications in modern medicine — and for good reason. Marketed under the brand names Ozempic and Wegovy, semaglutide has demonstrated remarkable results for both type 2 diabetes management and long-term weight loss. In this guide, we break down how semaglutide works, what the
GLP-1
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has reshaped the landscape of obesity medicine and type 2 diabetes management. Originally developed by Novo Nordisk, semaglutide mimics a naturally occurring gut hormone that regulates appetite, blood sugar, and digestion. It is currently available under three brand names: * Ozempic — injectable
Compounding
GLP-1
A new class of obesity treatment is on the horizon. CagriSema, the combination of cagrilintide and semaglutide developed by Novo Nordisk, has generated enormous interest after delivering over 20% average weight loss in Phase 3 clinical trials. What Is CagriSema? CagriSema is a fixed-dose, once-weekly subcutaneous injection combining two active
GLP-1
Semaglutide has transformed the treatment of type 2 diabetes and obesity. Marketed as Ozempic for diabetes management and Wegovy for chronic weight management, this once-weekly injectable GLP-1 receptor agonist has become one of the most prescribed medications in the United States — and for good reason. Clinical trials show average body
GLP-1
Semaglutide and tirzepatide have transformed obesity medicine. The average person on tirzepatide loses 20–22% of their body weight; on semaglutide, 15–17%. Those are numbers that previously required bariatric surgery. But there's a complication the prescribing literature doesn't emphasize enough: a meaningful portion of that
GLP-1
Semaglutide has become one of the most talked-about medications in modern medicine — and for good reason. Sold under brand names like Ozempic, Wegovy, and Rybelsus, this once-weekly injectable (and now oral) drug has demonstrated unprecedented weight loss results, cardiovascular benefits, and a growing list of potential therapeutic applications. Whether you&
GLP-1
If you've been diagnosed with PCOS and struggle with weight, irregular periods, or stubborn insulin resistance, you've probably heard about Ozempic — and wondered whether it might help. The answer, based on growing clinical evidence, is a cautious but increasingly confident: yes. Semaglutide, the GLP-1 receptor agonist
GLP-1
Two medications have transformed obesity treatment over the past few years: semaglutide (sold as Ozempic for diabetes, Wegovy for weight loss) and tirzepatide (Mounjaro for diabetes, Zepbound for weight loss). Both deliver remarkable results, but they work differently — and the evidence now clearly shows one outperforms the other on the
GLP-1
GLP-1